Aesculap Biologics reaches halfway mark in clinical trial for knee articular cartilage defects: 5 insights

Shayna Korol -   Print  |

Aesculap Biologics achieved 50 percent enrollment in its ongoing phase 3 clinical trial of Novocart 3D, an autologous chondrocyte transplantation system designed to treat articular cartilage defects of the knee.

Five things to know:

1. As of Feb. 28, approximately 117 of the expected 233 study participants have been treated in the study.

2. The multicenter, prospective, randomized, partially-blinded study is designed to evaluate the safety and efficacy of Novocart 3D compared to microfracture in the treatment of articular cartilage defects of the knee.

3. Since 2003, Novocart 3D has been used to treat more than 18,000 patients.

4. Researchers aim to use the study results to seek regulatory approval for Novocart 3D in the U.S.

5. Last year marked the highest enrollment year for the study to date. "We are pleased with the momentum the trial experienced in 2018 and the overall enthusiasm and commitment from the patients and the 30-plus clinical sites currently active in the United States and Canada," said Robert C. Spiro, PhD, senior vice president of Aesculap Biologics.

More articles on biologics:
Dr. Roger Hartl: The biggest opportunity in spinal biologics
Medtronic launches demineralized bone matrix for spine, orthopedics in Japan – 5 key notes
Cardinals' Carlos Martinez receives PRP injection at Andrews Institute for Orthopaedics and Sports Medicine — 4 insights

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers